Full-Time
Posted on 12/13/2025
Largest independent home infusion therapy provider
No salary listed
Tampa, FL, USA
In Person
| , |
Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Norfolk, Virginia
Founded
1979
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Paid Time Off
Bonding Time Off
401(k) Retirement Plan
401(k) Company Match
Health Savings Account/Flexible Spending Account
Flexible Spending Accounts
Tuition Reimbursement
Family Support
Mental Health Support
Company Paid Life Insurance
Award/Recognition Programs
Option Care Health has expanded its revolving credit facility by $450 million to $850 million and increased its share repurchase authorisation to $1 billion, whilst reaffirming its 2026 guidance. The moves strengthen liquidity and signal management confidence in cash generation. The expanded buyback and credit facility provide greater flexibility for growth investments and capital returns, though near-term focus remains on executing guidance and managing reimbursement pressures. The company's narrative projects $7 billion revenue and $302.2 million earnings by 2029, implying 7.5% annual revenue growth. Analyst fair value estimates range widely from $3.66 to $40.09 per share, with the upper estimate suggesting 46% upside from current prices.
MicroCare Medical welcomes Matt Lingenfelter as national sales manager, healthcare. March 09, 2026 MicroCare Medical is pleased to welcome Matt Lingenfelter as national sales manager, healthcare. With more than 20 years of experience in healthcare sales and leadership, Matt will help drive national growth and strengthen partnerships for the MicroCare Medical instrument care and infection prevention solutions. In this role, Matt will guide healthcare sales strategy across the U.S., focusing on expanding key accounts, building strong distributor relationships, and supporting the sales team. He will also work closely with marketing, operations, and product development to ensure MicroCare continues delivering solutions that meet the evolving needs of healthcare professionals. Before joining MicroCare, Matt held leadership roles with Option Care Health, Belimed, and Aesculap, where he developed deep expertise in surgical instrumentation, endoscopic technologies, and hospital system support. "Matt's experience and understanding of healthcare systems make him a fantastic addition to our team," said Ray Bellavance, vice president of global sales and marketing at MicroCare. "We're excited to have him help grow our healthcare business and strengthen partnerships across the country."
Option Care Health reported a 13% revenue increase in Q4 2025, with acute therapies growing in the mid-teens and chronic therapies in the low double digits. The company served over 315,000 unique patients and improved operational efficiency, with 40% of claims now processed without human intervention. For 2026, the company issued revenue guidance of $5.8 billion to $6 billion, incorporating a 400 basis point headwind from Stelara biosimilar conversions and Inflation Reduction Act impacts. Adjusted EBITDA is projected at $480 million to $505 million, accounting for a $25 million to $35 million gross profit headwind from Stelara transitions. Operating cash flow is expected to exceed $340 million, representing over 30% growth. The company plans to launch at least two new pharmaceutical manufacturer programmes and expand its infusion clinic model to support higher-acuity therapies.
EEOC sues Option Care Health, Inc. for pregnancy discrimination.
Quince Therapeutics selects Option Care Health as specialty infusion therapy provider for administration of lead asset eDSP.